Rapamycin Dosing for Longevity: Protocols, Timing & Clinical Considerations

At a Glance

Rapamycin (sirolimus) has moved from transplant medicine into serious longevity discussions largely because of one consistent finding: it extends lifespan in every animal model tested — including mice, flies, worms, and yeast — even when administration begins in middle or old age. The Interventions Testing Programme (ITP) at NIA demonstrated 14–23% lifespan extension in mice starting rapamycin at 600 days of age, an age equivalent to roughly 60 human years.

The mechanism is the inhibition of mechanistic target of rapamycin complex 1 (mTORC1), the cell’s master growth-and-proliferation switch. Chronic mTOR hyperactivation is linked to cellular senescence, reduced autophagy, mitochondrial dysfunction, and the pro-inflammatory secretome that drives most age-related diseases. Intermittently inhibiting mTORC1 appears to recalibrate this signalling without the full immunosuppression seen with transplant-level dosing.

This article focuses entirely on the dosing question: how much, how often, when, and how to monitor.

Why Dosing Strategy Matters More Than the Drug Itself

Rapamycin at transplant doses (1–5 mg/day continuously) produces well-characterised adverse effects: impaired wound healing, hyperlipidaemia, thrombocytopaenia, stomatitis, and significant immunosuppression leading to opportunistic infections. These risks are acceptable for someone who would otherwise reject a kidney — they are not acceptable for a healthy 50-year-old optimising health span.

The insight that changed the field came from work on the two mTOR complexes. mTORC1 is acutely and reversibly inhibited by rapamycin and is the target relevant to longevity signalling. mTORC2 — which governs glucose metabolism and AKT signalling — is inhibited only with prolonged, continuous rapamycin exposure. Chronic mTORC2 inhibition is the primary driver of the drug’s metabolic side effects, including insulin resistance and dyslipidaemia. The liver is the organ where this dynamic plays out most consequentially — for a detailed look at hepatic mTOR signalling and MASLD, see rapamycin and liver metabolic health.

Intermittent, once-weekly dosing sustains mTORC1 inhibition during the 24–48 hour post-dose window while allowing mTORC2 to recover before the next dose. This is not a compromise — it is a mechanistically superior strategy for the longevity use case.

The Evidence Base for Intermittent Dosing

The human evidence, while still building, is more substantial than many appreciate:

Mannick et al. (2014, 2018) — TORC1 inhibitor in older adults: The everolimus (rapalog) study in adults 65+ given 0.5 mg/day or 5 mg/weekly before influenza vaccination showed improved immune function with the weekly dose, not the daily. Weekly dosing also produced fewer side effects. This was the first controlled human data showing immunostimulation — not immunosuppression — at the lower intermittent dose.

Kaeberlein lab survey data (2021): A self-reported survey of 333 individuals taking rapamycin for longevity found the median dose of 5 mg/week was associated with modest and manageable side effects, with mouth sores and mild immune susceptibility being most common. Serious adverse events were rare.

AgelessRx PEARL trial (ongoing): The first randomised, placebo-controlled trial specifically in healthy older adults (>50 years) using 5 mg/week. Interim self-reported data suggest improved self-assessed healthspan scores with low adverse event rates, though blinded biomarker data are pending.

Dog Aging Project (2024): Rapamycin 0.05–0.1 mg/kg/week in companion dogs demonstrated cardiac benefit (improved systolic function) and good safety at 10 weeks, with longer-term data accumulating.

The human RCT data are still limited — this is an honest constraint. Practitioners and patients initiating rapamycin for longevity are doing so on strong mechanistic and animal evidence with emerging, early-phase human signal.

Dosing Protocols in Clinical Practice

Starting Protocol

The clinical principle is to begin low and titrate to effect while monitoring for side effects.

Week 1–4: 2 mg orally once weekly, taken fasting (absorption is modestly improved and more predictable without food)

Week 5–12: Increase to 3 mg weekly if tolerating well (no mouth sores, no significant fatigue, labs stable)

Week 13 onward: Individualise based on response, labs, and goals. Most patients in longevity practice settle between 3–6 mg/week

A minority of patients tolerate and choose higher doses (up to 10 mg/week), though the benefit-risk calculus becomes less clear above 6 mg, and I do not routinely recommend this without compelling clinical justification.

Timing Within the Week

Consistency matters more than which day is chosen. Most patients dose on a Monday or Saturday to align with lifestyle patterns. Because rapamycin has a half-life of approximately 60 hours, the decision to dose with food or fasting primarily affects peak concentration rather than total exposure — fasting dosing gives a slightly higher, earlier peak, which may be preferable for the mTORC1 inhibition window.

Cycling vs Continuous Dosing

Two approaches exist in practice:

• Continuous weekly dosing (52 weeks/year): More common in published survey data. Provides ongoing mTORC1 inhibition. Better studied.
• 3 months on / 1 month off cycles: Proposed to allow mTORC2 full recovery and reduce cumulative immunosuppression. Less studied but theoretically reasonable. Some practitioners prefer this for younger patients or those with infection-prone histories.

There is currently no comparative human data favouring one approach over the other. I use continuous weekly dosing in most patients and reserve cycling for those who report recurrent infections or who wish to reduce cumulative exposure.

Lab Monitoring Framework

Rapamycin is not a supplement — it requires clinical oversight. The following schedule represents my standard monitoring approach for healthy longevity patients:

Before Starting

• Complete blood count (CBC): Baseline platelet count, lymphocyte count
• Comprehensive metabolic panel (CMP): Renal and hepatic function
• Fasting lipid panel: Rapamycin can worsen hypertriglyceridaemia
• HbA1c and fasting glucose: mTORC1 inhibition affects insulin signalling
• Hepatitis B and C serology: Reactivation risk is real with immunomodulation
• Sirolimus trough level (after 4–6 weeks of dosing): Optional but useful for pharmacokinetic outliers

Every 3 Months for Year One

CBC, CMP, lipid panel, HbA1c. Adjust dose or discontinue based on:

• Platelet count below 100,000 → dose reduction or pause
• Triglycerides above 400 mg/dL → statin consideration, potential dose reduction
• Creatinine rise >25% from baseline → investigate, consider dose reduction

Annually Once Stable

Full panel plus sirolimus trough level if there have been any concerning changes in response.

Drug Interactions: The CYP3A4 Problem

Rapamycin is metabolised almost entirely by CYP3A4 hepatic enzymes. This creates clinically meaningful interactions that must be assessed before prescribing:

Strong CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, grapefruit juice, verapamil): Can multiply rapamycin blood levels 5–20 fold. Concurrent use requires either rapamycin dose reduction or avoidance of the inhibitor.

Strong CYP3A4 inducers (rifampicin, carbamazepine, St John’s Wort, phenytoin): Can reduce rapamycin levels by 60–90%, rendering the dose ineffective.

Commonly used longevity supplements to watch:

• Berberine: Modest CYP3A4 inhibition — some practitioners reduce rapamycin to 1–2 mg/week when combining
• Curcumin (high-dose): Mild inhibitor — monitor
• CBD oil: Moderate inhibitor at high doses

The practical approach: build a complete medication and supplement list, check CYP3A4 interactions, and obtain a sirolimus trough level 4–6 weeks after any significant medication change.

Who Should Not Take Rapamycin

Clear contraindications for longevity use:

• Active infection of any kind — including dental infections, skin infections, or unresolved respiratory illness. Defer rapamycin until fully resolved.
• Hepatic impairment (Child-Pugh B or C): Dramatically increases drug levels and toxicity risk
• Pregnancy or breastfeeding: Teratogenic in animal models; contraindicated absolutely
• Thrombocytopenia at baseline: Any platelet count below 100,000 warrants extreme caution
• Pre-existing severe hypertriglyceridaemia: Rapamycin can worsen this to pancreatitis-risk levels
• Uncontrolled diabetes: mTORC2 inhibition with chronic dosing worsens glucose handling

For a full discussion of side effects by dose tier and the mechanism behind each, including how to manage mouth ulcers and elevated lipids, see Rapamycin Side Effects: Longevity Dose vs Transplant Dose.

Relative cautions requiring shared decision-making:

• History of recurrent infections or immunodeficiency
• Current high-intensity athletic training (mTOR inhibition may impair muscle protein synthesis — some athletes cycle off rapamycin around heavy training blocks)
• Concurrent use of multiple immunomodulatory agents

Rapamycin in the Context of a Longevity Stack

Rapamycin does not exist in isolation in most clinical longevity protocols. The interaction points worth knowing:

Rapamycin + Metformin: Theoretically complementary — metformin activates AMPK which inhibits mTOR via a parallel pathway. Some evidence in C elegans of additive benefit. Human data absent. Combined use is practised but not well-studied.

Rapamycin + Senolytics (quercetin + dasatinib, fisetin): Senolytics clear existing senescent cells; rapamycin prevents the creation of new ones via mTOR-mediated senescence pathways. Logical combination. I typically pulse senolytics quarterly on separate days from rapamycin.

Rapamycin + NAD+ precursors (NMN/NR): NAD+ supports mitochondrial function and sirtuin activity. Rapamycin upregulates autophagy. These mechanisms are largely complementary, and this combination is common in longevity clinical practice.

Rapamycin + Resistance training: This is the main biological tension. mTOR signalling is essential for muscle hypertrophy in response to resistance training. If muscle building is a primary goal, consider either avoiding rapamycin, using very low doses, or taking rapamycin on non-training days and at least 48 hours before heavy sessions. The longevity tradeoff between mTOR inhibition and muscle mass preservation is a genuine clinical question without a resolved answer.

Related Articles

• Rapamycin for Longevity: What the Evidence Actually Shows
• Rapamycin vs Metformin: Comparing Two Longevity Drugs
• Metformin Dosage Guide for Longevity
• Senolytics: Quercetin, Fisetin and Clearing Zombie Cells
• NMN vs NR vs NAD+: Which Precursor Is Right for You?

References

1. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. doi:10.1038/nature08221

2. Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179. doi:10.1126/scitranslmed.3009892

3. Mannick JB, Morris M, Hockey HP, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. 2018;10(449):eaaq1564. doi:10.1126/scitranslmed.aaq1564

4. Bitto A, Ito TK, Pineda VV, et al. Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. eLife. 2016;5:e16351. doi:10.7554/eLife.16351

5. Kaeberlein M, Creevy KE, Promislow DEL. The dog aging project: translational geroscience in companion animals. Mamm Genome. 2016;27(7-8):279-288. doi:10.1007/s00335-016-9638-7

6. Kennedy BK, Lamming DW. The mechanistic target of rapamycin: the grand conductor of metabolism and aging. Cell Metab. 2016;23(6):990-1003. doi:10.1016/j.cmet.2016.05.009

7. Arriola Apelo SI, Lamming DW. Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island. J Gerontol A Biol Sci Med Sci. 2016;71(7):841-849. doi:10.1093/gerona/glw090